Isolated nail psoriasis may be a sign of psoriatic arthritis

Published Date: 02 Mar 2023

In a review of 87 patients, the authors recorded the clinical and histological characteristics of patients with nail psoriasis.

Read Full News

Latest News

Insulin Resistance Detected Early May Guide HS Therapy

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

Dermatomyositis: Targeted Drug Shows Promise vs Placebo

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Melasma: A New Era of Topical Treatment Options Galore

Combination therapies remain key as multiple agents for melasma hit the market.

Research Uncovers Mental Health Toll of Alopecia on Women

Black women are at greater risk for depression and anxiety, and scarring forms are linked to more disorders.

ICI-Related Toxicity Diagnoses Differ for Dark vs Light Skin

A review of published studies suggests that skin toxicities related to checkpoint inhibitors may be managed differently in patients with skin of color vs lighter skin tones.

Consensus Defines Vitiligo Severity, Relapse Beyond BSA

An international consensus study establishes standardized definitions for vitiligo severity and relapse, emphasizing that body surface area alone is insufficient to capture disease burden.

Todays Updates

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Todays Updates

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Latest News

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Combination therapies remain key as multiple agents for melasma hit the market.

Black women are at greater risk for depression and anxiety, and scarring forms are linked to more disorders.

A review of published studies suggests that skin toxicities related to checkpoint inhibitors may be managed differently in patients with skin of color vs lighter skin tones.

An international consensus study establishes standardized definitions for vitiligo severity and relapse, emphasizing that body surface area alone is insufficient to capture disease burden.

News All Time

FDA OKs Linerixibat for Cholestatic Pruritus

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.

Distinct Comorbidity Pattern Hinders Remission in Lupus

Patients with lupus face a high burden of comorbidities, with the presence of at least one of seven key conditions linked to 55%-60% lower odds of achieving remission or a low disease activity state.

Children With Autism Face Growing Unmet Healthcare Needs

A cross-sectional study examines annual trends in unmet healthcare needs among over 8000 children with autism.

HSV-1 May Be Increasing in Infants

A new study suggests that HSV-1 has become the dominant subtype among newborns.

Secukinumab Gets FDA Nod for Adolescent HS

Weight-based injectable’s approval is based in part on other pediatric indications.

Low-Beta Radiation Patch Offers Alternative NMSC Treatment

Similar to brachytherapy, OncoPatch could be an option for patients who have superficial lesions or who aren’t surgical candidates.

What Does FDA Food Pyramid Mean for Cancer Risk and Care?

Much of the new FDA food guidance aligns with existing advice, but some areas may introduce confusion to advising patients on diet and cancer prevention and survival.

UK Approves New JAK Inhibitor for Severe Alopecia

Deuruxolitinib is the latest JAK inhibitor to enter the UK alopecia areata treatment landscape, pending a NICE decision on NHS access.

Tildrakizumab Now Under FDA Review for Psoriatic Arthritis

Full results from the pivotal trials submitted to support approval have not yet been reported.

Early Intensive Therapy Best for PsA With Poor Prognosis

Early intensive treatment for PsA with csDMARDs or 6 months of TNFi is superior to standard step-up care, and better outcomes were maintained at 48 weeks in the TNFi group.

Guselkumab Effective After TNF Inhibitor Failure in PsA

Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.

Meta-analysis: Dermoscopic Features Distinguish ALM

Parallel ridge and multicomponent patterns are the most common dermoscopic features that identify acral lentiginous melanoma, according to a meta-analysis.

Geriatric Oncology Has Become Personalized: Here’s Why

As immunotherapy reshaped cancer care, geriatric oncology shifted toward personalized, geriatric assessment-guided treatment that prioritizes function, safety, and what matters most to older adults.

Hidradenitis Suppurativa Raises Risk for Self-Harm, Suicide

Patients with hidradenitis suppurativa have a higher risk for self-harm and suicide than matched control individuals, according to the results of a Danish cohort study.

Perianal Abscess Tied to Crohn's Disease Risk in Older Kids

Older children with perianal abscess or fistula-in-ano, especially those with recurrent perianal abscess or fistula-in-ano or gastrointestinal symptoms, are more likely to develop Crohn's disease.

Bimekizumab Not Tied to Mental Health Risk, Study Suggests

A study suggests that bimekizumab does not increase the risk for depression or suicidal ideation compared with IL-23 inhibitors in adults with psoriasis.

Recommended News For You

Health of Myeloma Patient's Marriage Tied to Recovery After Transplant

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

Clinical trial could lead to new 'gold standard' test for prostate cancer detection

Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link

For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.

Joe Biden has prostate cancer with bone spread. An oncologist explains what you need to know

Recommended Articles For You

Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results 

Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy 

Different Types of Blood Dyscrasias  

HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A new way to measure suicide risk?

2.

Dual-action mRNA vaccine takes aim at aggressive skin cancer

3.

Coupling dye and fiducial marking can improve precision in pulmonary nodule surgical resection

4.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

5.

Pressing the Sleep button could have a positive impact on cognition.

1.

Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer

2.

Cutting-Edge Cancer Treatments: Innovations and Outcomes in Non-Hodgkin Lymphoma

3.

Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained

4.

Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers

5.

Liquid Biopsy in SCLC: cfDNA Profiling for Diagnosis and Treatment Monitoring

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

3.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

4.

Thromboprophylaxis In Medical Settings

5.

Managing CNS diseases at the point of diagnosis in ALK + NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot